Ipilimumab-Induced Enteritis without Colitis: A New Challenge

INTRODUCTION: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first therapy shown to prolong survival in a large, randomized clinical trial. However, immune-related adverse events are common...

Descripción completa

Detalles Bibliográficos
Autores principales: Messmer, Marcus, Upreti, Sunita, Tarabishy, Yaman, Mazumder, Nikhilesh, Chowdhury, Reezwana, Yarchoan, Mark, Holdhoff, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126596/
https://www.ncbi.nlm.nih.gov/pubmed/27920706
http://dx.doi.org/10.1159/000452403

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126596/
https://www.ncbi.nlm.nih.gov/pubmed/27920706
http://dx.doi.org/10.1159/000452403

Ejemplares similares